Repso Withdrawal of the marketing authorisation in the European Union
On 19 July 2017, the European Commission withdrew the marketing authorisation for Repso (leflunomide) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Teva B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. Repso was granted marketing authorisation in the EU on 14 March 2011 for the treatment of active rheumatoid and active psoriatic arthritis. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2016. Repso is a generic medicine of Arava. There are other generic medicinal products of Arava authorised and marketed in the EU. The European Public Assessment Report (EPAR) for Repso will be updated accordingly to reflect the fact that the marketing authorisation is no longer valid.
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact
Apr 18, 2008 - European Commission and Parliament to add a 'European dimension' ..... priorities figured the adoption of curricular themes that portrayed "the.
Jan 1, 2017 - download (*EVPM). ICSR creation. ICSR ... The following illustration shows the report's filters. EV-M5b - EVDAS .... Grouping is a manual activity performed by the Agency to facilitate such analysis. ...... The ICSR is provided in PDF f
identity, a uniquely European sense of self and conception of the good life, has ... Email: [email protected] .... that nation states have appealed to but by subscription to democratic values and ...... European Parliament Press Service.
The EU for its part had raised the issue of the export restraints as one of a number of ..... China is a leading global producer of all nine of these Raw Materials. ..... quota; (iii) the "business management capacity" of the applicant; and (iv) the.
